Aurelia H. M. de Vries Schultink

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker et al. · Investigational New Drugs · 2018 · 34 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis

Carla Bastida, Virginia Ruíz-Esquide, Mariona Pascal et al. · British Journal of Clinical Pharmacology · 2018 · 23 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Aurelia H. M. de Vries Schultink, Xanthippi Alexi, Erik van Werkhoven et al. · Breast Cancer Research and Treatment · 2016 · 21 citations · Full text

Medicine, Oncology, Pharmacology +14

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

Aurelia H. M. de Vries Schultink, Annelies H. Boekhout, Jourik A. Gietema et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2018 · 20 citations · Full text

Medicine, Cardiology, Pharmacology +17

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy

Aurelia H. M. de Vries Schultink, Alwin D. R. Huitema, Jos H. Beijnen · The Breast · 2018 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14